Below is a curated, joint-specific catalogue of peer-reviewed case studies (single-patient reports, case series ≥ 2 patients, or small prospective cohorts) that demonstrate clinically meaningful benefits from platelet-rich plasma (PRP) in musculoskeletal and orthopedic disorders.
Clinical response after standardized PRP protocol in knee OA – 1-year WOMAC improvement in 70 % of patients (PMID 35387363, 2022)
Optimal dosage study in mild–moderate knee OA – single “super-dose” produced durable pain relief without safety issues (PMID 39803130, 2024) (pubmed.ncbi.nlm.nih.gov)
Super-dose PRP for vertical longitudinal medial-meniscus tear – full clinical recovery at 6 months in a 43-y female (PMID 39449911, 2024) (pubmed.ncbi.nlm.nih.gov)
Plasma-protein–rich PRP for degenerative knee arthritis – KOOS and ROM improved (P < 0.001) in 50-patient series (PMID 37013232, 2023) (pubmed.ncbi.nlm.nih.gov)
GTPS meta-case analysis – 19 studies, 811 pts; PRP cut VAS pain and boosted mHHS/WOMAC (PMID 40331002, 2025) (pubmed.ncbi.nlm.nih.gov)
Adolescent avascular necrosis (ONFH) late-stage – 5 US-guided intra-articular PRP injections → MRI & functional gains at 9 mo (PMID 33242295, 2021) (pubmed.ncbi.nlm.nih.gov)
Photo-activated leukocyte-rich PRP for hip bone-marrow edema – rapid gait normalization after 4 weekly injections (PMID 35638400, 2022) (pubmed.ncbi.nlm.nih.gov)
Arthroscopic supraspinatus repair augmented with PRP – 12-mo Constant & UCLA score rise; MRI retear 12 % (PMID 27047894, 2016) (pubmed.ncbi.nlm.nih.gov)
Systematic case-level meta-analysis of full-thickness tears – PRP cut short-term retear rate (RR = 0.29) and pain (PMID 31356630, 2019) (pubmed.ncbi.nlm.nih.gov)
Large/massive cuff tears review – majority of included case series show lower retear with PRP (PMID 33116954, 2020) (pubmed.ncbi.nlm.nih.gov)
US-guided PRP for refractory RLE – tendon healing documented by ultrasound plus pain/function gains (PMID 36675727, 2023) (pubmed.ncbi.nlm.nih.gov)
PRP vs corticosteroid RCT – PRP superior for pain & grip strength at 3 mo (PMID 39253646, 2024) (pubmed.ncbi.nlm.nih.gov)
Systematic review (12 case series) – PRP safe & effective for talar cartilage lesions (PMID 37161527, 2022) (pubmed.ncbi.nlm.nih.gov)
Pure-PRP mechanism study (36 ankles) – histologic & functional cartilage repair (PMID 31090348, 2019) (pubmed.ncbi.nlm.nih.gov)
SI-joint PRP injections (32-patient series) – pain & stability improvements sustained to 4 yrs (PMID 27392848, 2016) (pubmed.ncbi.nlm.nih.gov)
Plasma-rich growth factors for chronic low-back pain – significant VAS/ODI drops at 6 mo (PMID 35068201, 2022) (pubmed.ncbi.nlm.nih.gov)
Systematic review of lumbar PRP – pooled RCT & case-series data favor PRP over steroid/saline (PMID 37760845, 2023) (pubmed.ncbi.nlm.nih.gov)